174 related articles for article (PubMed ID: 38267634)
1. Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer.
Wang J; Sun N; Kunzke T; Shen J; Feuchtinger A; Wang Q; Meixner R; Gleut RL; Haffner I; Luber B; Lordick F; Walch A
Br J Cancer; 2024 Apr; 130(6):1036-1045. PubMed ID: 38267634
[TBL] [Abstract][Full Text] [Related]
2. Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment.
Yoon SH; Kim YH; Lee YJ; Park J; Kim JW; Lee HS; Kim B
PLoS One; 2016; 11(8):e0161278. PubMed ID: 27517841
[TBL] [Abstract][Full Text] [Related]
3. HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study.
Haffner I; Schierle K; Raimúndez E; Geier B; Maier D; Hasenauer J; Luber B; Walch A; Kolbe K; Riera Knorrenschild J; Kretzschmar A; Rau B; Fischer von Weikersthal L; Ahlborn M; Siegler G; Fuxius S; Decker T; Wittekind C; Lordick F
J Clin Oncol; 2021 May; 39(13):1468-1478. PubMed ID: 33764808
[TBL] [Abstract][Full Text] [Related]
4. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
Wang H; Li B; Liu Z; Gong J; Shao L; Ren J; Niu Y; Bo S; Li Z; Lai Y; Lu S; Gao J; Shen L
Eur J Cancer; 2018 Jan; 88():92-100. PubMed ID: 29207318
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer.
Wakatsuki T; Yamamoto N; Sano T; Chin K; Kawachi H; Takahari D; Ogura M; Ichimura T; Nakayama I; Osumi H; Matsushima T; Suenaga M; Shinozaki E; Hiki N; Ishikawa Y; Yamaguchi K
J Gastroenterol; 2018 Nov; 53(11):1186-1195. PubMed ID: 29633013
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.
Li Q; Li H; Jiang H; Feng Y; Cui Y; Wang Y; Ji Y; Yu Y; Li W; Xu C; Yu S; Zhuang R; Liu T
Clin Transl Oncol; 2018 Jun; 20(6):695-702. PubMed ID: 29168107
[TBL] [Abstract][Full Text] [Related]
7. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
Xu C; Liu Y; Jiang D; Li Q; Ge X; Zhang Y; Huang J; Su J; Ji Y; Hou J; Lu S; Hou Y; Liu T
Oncotarget; 2017 May; 8(20):33185-33196. PubMed ID: 28388541
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer.
Yagi S; Wakatsuki T; Yamamoto N; Chin K; Takahari D; Ogura M; Ichimura T; Nakayama I; Osumi H; Shinozaki E; Suenaga M; Fujisaki J; Ishikawa Y; Yamaguchi K; Namikawa K; Horiuchi Y
Gastric Cancer; 2019 May; 22(3):518-525. PubMed ID: 30328533
[TBL] [Abstract][Full Text] [Related]
9. Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients.
Wang J; Kunzke T; Prade VM; Shen J; Buck A; Feuchtinger A; Haffner I; Luber B; Liu DHW; Langer R; Lordick F; Sun N; Walch A
Clin Cancer Res; 2022 Jul; 28(13):2865-2877. PubMed ID: 35395077
[TBL] [Abstract][Full Text] [Related]
10. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
Rivera F; Romero C; Jimenez-Fonseca P; Izquierdo-Manuel M; Salud A; Martínez E; Jorge M; Arrazubi V; Méndez JC; García-Alfonso P; Reboredo M; Barriuso J; Muñoz-Unceta N; Jimeno R; López C
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1175-1181. PubMed ID: 30927036
[TBL] [Abstract][Full Text] [Related]
11. Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.
Takahashi N; Furuta K; Taniguchi H; Sasaki Y; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Hamaguchi T; Shimada Y; Yamada Y
Oncotarget; 2016 Jan; 7(4):4925-38. PubMed ID: 26716644
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis.
Wang HB; Liao XF; Zhang J
Medicine (Baltimore); 2017 Nov; 96(44):e8437. PubMed ID: 29095284
[TBL] [Abstract][Full Text] [Related]
13. Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.
Müller V; Clemens M; Jassem J; Al-Sakaff N; Auclair P; Nüesch E; Holloway D; Shing M; Bang YJ
BMC Cancer; 2018 Mar; 18(1):295. PubMed ID: 29544445
[TBL] [Abstract][Full Text] [Related]
14. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.
Qiu MZ; Li Q; Wang ZQ; Liu TS; Liu Q; Wei XL; Jin Y; Wang DS; Ren C; Bai L; Zhang DS; Wang FH; Li YH; Xu RH
Int J Cancer; 2014 May; 134(10):2468-77. PubMed ID: 24155030
[TBL] [Abstract][Full Text] [Related]
15. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
Seo S; Ryu MH; Park YS; Ahn JY; Park Y; Park SR; Ryoo BY; Lee GH; Jung HY; Kang YK
Gastric Cancer; 2019 May; 22(3):527-535. PubMed ID: 30386954
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Factors in Patients with Advanced HER2-Positive Gastric Cancer Treated with Trastuzumab-Based Chemotherapy: a Cohort Study.
Marshall S; Wakatsuki T; Takahari D; Matsushima T; Ishizuka N; Nakayama I; Osumi H; Ogura M; Ichimura T; Shinozaki E; Chin K; Yamaguchi K
J Gastrointest Cancer; 2023 Jun; 54(2):475-484. PubMed ID: 35435573
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer.
Matsushita D; Uenosono Y; Arigami T; Yanagita S; Okubo K; Kijima T; Miyazono F; Hamanoue M; Hokita S; Nakashima S; Ohtsuka T; Natsugoe S
Cancer Chemother Pharmacol; 2021 Jun; 87(6):789-797. PubMed ID: 33641065
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective Analysis.
Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Cho EK; Shin DB; Yang JY; Kim HS; Lee WK; Sym SJ
Am J Clin Oncol; 2022 Feb; 45(2):61-65. PubMed ID: 34991106
[TBL] [Abstract][Full Text] [Related]
19. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
Roviello G; Aprile G; D'Angelo A; Iannone LF; Roviello F; Polom K; Mini E; Catalano M
Gastric Cancer; 2021 Jul; 24(4):765-779. PubMed ID: 33742317
[TBL] [Abstract][Full Text] [Related]
20. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
